Induction of immune responses to SIV antigens by mucosally administered vaccines

AIDS Research and Human Retroviruses

Volumn 15, Issue 16, 1999, Pages 1469-1476

  Moldoveanu, Zina ^a   Vzorov, Andrei N ^b   Huang, Wen Qiang ^a   Mestecky, Jiri ^a   Compans, Richard W ^b  

^a University of Alabama at Birmingham   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN;

ADOLESCENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INTRADERMAL DRUG ADMINISTRATION; INTRAGASTRIC DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0033229748     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299309982     Document Type: Article

References (38)

1. Alexander NJ, Gabelnick HL, and Spieler JM (eds): Heterosexual Transmission of AIDS. Wiley-Liss, New York, 1990.
2. McGhee JR, Czerkinsky C, and Mestecky J: Mucosal vaccines: An overview. In: Mucosal Immunology (Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, and McGhee JR, eds.), 2nd Ed. Academic Press, New York, 1999, pp. 741-758.
3. Mestecky J: The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7:265-276.
4. Waldman RH, Cruz J, and Rowe S: Intravaginal immunization of humans with Candida albicans. J Immunol 1972;109:662-664.
5. Ogra PL and Ogra SS: Local antibody response to poliovaccine in the female genital tract. J Immunol 1973;110:1307-1311.
6. Czerkinsky C, Prince SJ, Michalek SM, Jackson S, Russell MW, Moldoveanu Z, McGhee JR, and Mestecky J: IgA Antibody-producing cells in peripheral blood after antigen ingestion: Evidence for a common mucosal immune system in humans. Proc Natl Acad Sci USA 1987;84:2449-2453.
7. Mestecky J, Moldoveanu Z, Michalek SM, Morrow C, Compans RW, Schafer DP, and Russell MW: Current options for vaccine delivery systems by mucosal routes. J Controlled Release 1997; 48:243-257.
8. Morrow CD, Novak M, Ansardi DC, Porter DC, and Moldoveanu Z: Recombinant viruses as vectors for mucosal immunity. Curr Top Microbiol Immunol 1999;236:255-273.
9. Moss B: Vaccinia virus: A tool for research and vaccine development. Science 1991;252:1662-1667.
10. Paoletti E: Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA 1996;93:11349-11353.
11. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, and Small PA Jr: Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. Virology 1996;70: 6418-6424.
12. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, and Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
13. Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia, J, and Franchini G: Recombinant vaccine induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure. J Virol 1998;72:4170-4182.
14. Karacostas V, Nagashima K, Gonda MA, and Moss B: Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci USA 1989;86:8964-8967.
15. Shioda T and Shibuta H: Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 1990;175: 139-148.
16. Hu SL, Travis BM, Garrigues J, Zarling JM, Sridhar P, Dykers T, Eichberg JW, and Alpers C: Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 1990;179:321-329.
17. Vzorov AN, Tentsov YY, Grigoriev VB, Shulenin SA, Garaev MM, Bogdan OP, and Bukrinskaya AG: Formation of virus-like particles by HIV-1 Gag proteins, expressed by a recombinant vaccinia virus. Mol Biol (Mosk) 1990;24:1666-1674.
18. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, and Hu SL: Human immunodeficiency virus-like, nonreplicating, Gag-Env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990;64:2653-2659.
19. Vzorov AN, Bukrinsky MI, Grigoriev VB, Tentsov YY, and Bukrinskaya AG: Highly immunogenic human immunodeficiency virus like particles are produced by recombinant vaccinia virus-infected cells. AIDS Res Hum Retroviruses 1991;7:29-36.
20. Rovinski B, Haynes JR, Cao SX, James O, Sia C, Zolla-Pazner S, Matthews TJ, and Klein MH: Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: Implications for development of a cross-protective AIDS vaccine. J Virol 1992;66: 4003-4012.
21. Vzorov AN and Compans RW: Assembly and release of SIV Env proteins with full-length or truncated cytoplasmic domains. Virology 1996;221:22-33.
22. Chakrabarti S, Brechling K, and Moss B: Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 1985;5: 3403-3409.
23. de Vos T and Dick T: A rapid method to determine the isotype and specificity of coproantibodies in mice infected with Trichinella or fed cholera toxin. J Immunol Methods 1991;141:285-288.
24. Chackerian B, Haigwood NL, and Overbaugh J: Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 1995;213:386-394.
25. Wu Z, Qian G, Zhen QL, Narayan O, and Stephens EB: Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the "V3" domain. Virology 1996;222:184-192.
26. Moldoveanu Z, Russell MW, Wu HY, Huang WQ, Compans RW, and Mestecky J: Compartmentalization within the common mucosal immune system. Adv Exp Med Biol 1995;371A:97-101.
27. Robinson HL: DNA vaccines for immunodeficiency viruses. AIDS 1997;11:S109-S119.
28. Ritter GD Jr, Mulligan MJ, Lydy SL, and Compans RW: Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology 1993; 197:255-264.
29. Johnston PB, Dubay JW, and Hunter E: Truncations of the simian immunodeficiency virus transmember protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 1993;67:3077-3086.
30. Zingler K and Littman DR: Truncation of the cytoplsamic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity. J Virol 1993;67:2824-2831.
31. Spies CP and Compans RW: Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology 1994;203:8-19.
32. Vzorov A, Lea D, and Compans RW: Viral Immunol 1999;12 (in press).
33. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, and Sutter G: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996;397:7-13.
34. Gallichan S and Rosenthal KL: Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995;13:1589-1595.
35. Pal S, Peterson EM, and De La Maza LM: Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun 1996;64:5341-5348.
36. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, and Michalek SM: Salivary, nasal, genital and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and cholera toxin B subunit. Infect Immun 1996;64: 1272-1283.
37. Lubeck MD, Natuk RJ, Chengalvala M, Chanda PK, Murthy KK, Murthy S, Mizutani S, Lee S-G, Wade MS, Bhat BM, Bhat R, Dheer SK, Eichberg JW, Davis AR, and Hung PP: Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994;10:1443-1449.
38. Winchell JM, Van Kruiningen HJ, and Silbart LK: Mucosal immune response to an HIV C4/V3 peptide following nasal or intestinal immunization of rabbits. AIDS Res Hum Retroviruses 1997;13:881-889.